Stereotactic Ablative Radiotherapy for Early-stage Glottic Larynx Cancer

Glottic Carcinoma Clinical Trial

Official title: A Phase II Study of Glottic Larynx Stereotactic Ablative Radiotherapy (LT-SABR) for Early-Stage Glottic Larynx Cancer

Status Active, not recruiting

Clinical Trial Summary

The goal of treatment with radiation therapy is to deliver as high of a dose as possible to the target (tumor), while minimizing the dose to the normal tissues where late-side effects can drastically affect patient quality of life.

Clinical Trial Description

Radiation will be delivered twice per week for 5 fractions (42.5 Gy cohort, low-risk) or daily for 16 fractions (58.08 Gy cohort, moderate-risk).

Low-risk is defined by:

• Planning target volume (PTV) less than 10 cc, AND

• No reported smoking within 1 month from registration

Moderate-risk is defined by:

• Planning target volume (PTV) greater than or equal to 10 cc, OR

• Smoking within 1 month from registration (no more than 1 pack per day) ;

Related Conditions & MeSH terms

• Glottic Carcinoma
• Laryngeal Neoplasms

• NCT number: NCT03548285
• Study type: Interventional
• Source: University of Texas Southwestern Medical Center
• Status: Active, not recruiting
• Phase: N/A
• Start date: May 15, 2018
• Completion date: December 2024